English  |  正體中文  |  简体中文  |  總筆數 :2823024  
造訪人次 :  30236947    線上人數 :  639
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"zhu viola w"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 1-4 / 4 (共1頁)
1 
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-11-29T06:37:51Z An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; Lin, Chia-Chi; Soo, Ross A
臺大學術典藏 2021-08-22T00:00:09Z Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Subbiah, Vivek; Hu, Mimi I.; Wirth, Lori J.; Schuler, Martin; Mansfield, Aaron S.; Curigliano, Giuseppe; Brose, Marcia S.; Zhu, Viola W.; Leboulleux, Sophie; Bowles, Daniel W.; Baik, Christina S.; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F.; Lopes, Gilberto; Chia-Chi Lin; Godbert, Yann; Sarker, Debashis; Miller, Stephen G.; Clifford, Corinne; Zhang, Hui; Turner, Christopher D.; Taylor, Matthew H.
臺大學術典藏 2020-04-28 An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC Soo, Ross A; Chia-Chi Lin; Soo, Ross A;Chia-Chi Lin;Reungwetwattana, Thanyanan;Syn, Nicholas L;Ignatius Ou, Sai-Hong;Tchekmedyian, Nishan;Ock, Chan-Young;Ang, Yvonne L E;To, Hao;Nagasaka, Misako;Loong, Herbert H;Kim, Dong-Wan;YEN-TING LIN;Zhu, Viola W; Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne L E; Ock, Chan-Young; Tchekmedyian, Nishan; Ignatius Ou, Sai-Hong; Syn, Nicholas L; Reungwetwattana, Thanyanan
臺大學術典藏 2020-04-28 An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC Soo, Ross A; Chia-Chi Lin; Soo, Ross A;Chia-Chi Lin;Reungwetwattana, Thanyanan;Syn, Nicholas L;Ignatius Ou, Sai-Hong;Tchekmedyian, Nishan;Ock, Chan-Young;Ang, Yvonne L E;To, Hao;Nagasaka, Misako;Loong, Herbert H;Kim, Dong-Wan;YEN-TING LIN;Zhu, Viola W; Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne L E; Ock, Chan-Young; Tchekmedyian, Nishan; Ignatius Ou, Sai-Hong; Syn, Nicholas L; Reungwetwattana, Thanyanan

顯示項目 1-4 / 4 (共1頁)
1 
每頁顯示[10|25|50]項目